LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

REVOLUTION Medicines Inc

Geschlossen

BrancheGesundheitswesen

38 2.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

37.21

Max

38.23

Schlüsselkennzahlen

By Trading Economics

Einkommen

-34M

-248M

EPS

-1.13

Gewinnspanne

-74.379

Angestellte

700

EBITDA

-24M

-261M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+85.52% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-258M

6.7B

Vorheriger Eröffnungskurs

35.74

Vorheriger Schlusskurs

38

Nachrichtenstimmung

By Acuity

34%

66%

88 / 372 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

REVOLUTION Medicines Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Aug. 2025, 22:51 UTC

Ergebnisse

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Rev $4.01B

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Adj EPS $1.84

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H EPS $1.82

27. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. Aug. 2025, 23:39 UTC

Ergebnisse

Correction to Nvidia Earnings Article -- WSJ

27. Aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. Aug. 2025, 22:58 UTC

Ergebnisse

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. Aug. 2025, 22:57 UTC

Ergebnisse

South32 FY Free Cash Flow $192 Million

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Total Capital Expenditure $1.35 Billion

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. Aug. 2025, 22:55 UTC

Ergebnisse

South32 Net Cash $123 Million at June 30

27. Aug. 2025, 22:54 UTC

Ergebnisse

South32: Focused on Maintaining Strong Operating Momentum

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32 Extends Capital Management Program for 12 Months

27. Aug. 2025, 22:52 UTC

Ergebnisse

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. Aug. 2025, 22:45 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. Aug. 2025, 22:43 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. Aug. 2025, 22:43 UTC

Ergebnisse

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources Net Debt $123 Million at June 30

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer-Vergleich

Kursveränderung

REVOLUTION Medicines Inc Prognose

Kursziel

By TipRanks

85.52% Vorteil

12-Monats-Prognose

Durchschnitt 69.16 USD  85.52%

Hoch 80 USD

Tief 37.91 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für REVOLUTION Medicines Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

13

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

40.67 / 41.96Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

88 / 372 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.